HLA Typing | NGS | Next Generation Sequencing

NanoTYPE™

Nanopore-based long-read sequencing technology offering a revolutionary change in the clinical routine of HLA genotyping.

NANOTYPE MONO™ & MONOall™

NANOTYPE MONO™ & MONOall™ are Omixon’s latest development specifically designed for single locus testing. These kits are now available as RUO products (Research Use Only) in 24 and 96 formats.

HoloGRAFT ONE™

HoloGRAFT ONE™ is an innovative test intended for research applications to measure the absolute and relative quantity of donor-derived cell-free DNA in transplant recipients based.

What we do

Omixon is a molecular diagnostics company dedicated to transitioning the HLA community to Next Generation Sequencing (NGS) technologies.

Highest level of leadership

Our key opinion leaders and major collaborators in the HLA community have provided the highest level of leadership for several decades and helped pave the way for the adoption of NGS.

Omixon has evolved into a global molecular diagnostics company that is currently focused on driving the adoption of NGS in the clinic with Holotype HLA™ and other NGS-based HLA genotyping Assay and Software products.

NGS FOR HLA EXPERTS

Our flagship product Holotype HLA™ was designed in a clinical lab at the Children’s Hospital of Philadelphia by Professor Dimitri Monos. It is a combination NGS Assay and Software product for use on Illumina® sequencers.

Believe the data:

150+ HLA labs trained onsite worldwide
50+ HLA labs in clinical routine worldwide
20+ customers using CE-IVD products in Europe
12 labs ASHI or CAP accredited in North-America
20 labs EFI accredited in Europe

NANOTYPE EU-IVDR

NEW! HOLOGRAFT ONE

Omixon Blog

Werfen acquires Omixon

16/10/2024

Barcelona, Spain May 15, 2024.- Werfen announced today that it has agreed to acquire Omixon, a privately held corporation...

Events

EVENTS 2024

TESTIMONIALS

Testimonials

The NanoTYPE HLA typing assay is optimally designed and supported by a clear protocol so that the workflow can be easily integrated into any H&I laboratory to be used in daily routine. Dr.Monica Dutescu, MD, PhD, National HLA Laboratory, National Blood Transfusion Institute "Prof.Dr. C.T. Nicolau"
“Once again, I congratulate the new version 4.2 of the Twin which is much faster and optimized in processing time and alignment." Romulo Vianna, PhD Rio de Janeiro, State University |UERJ
"It's astonishing sometimes how easily HLA Twin deals with challenging samples like rare alleles. The data is there - you're just convinced!" Alexandre Walencik, Biologiste Médical, Laboratoire HLA - Nantes
“We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques. Omixon was also the strongest performer in terms of total mutations detected with a 99.14% detection sensitivity in single-end mode.”Gavin Oliver, Bioinformatics Team Leader at Almac
"The Holotype HLA method is optimally designed for the service laboratory user and is supported by a clear and easily followed protocol which facilitates method performance. Omixon is an enabling and supportive company that works with you to deliver successful outcomes for your programme rather than sales."Brendan Clarke, HLA Lab Director at Leeds St. James's University Hospital
“Omixon has developed an excellent direct genotyping method from next-generation sequencing that addresses the major problems associated with HLA calling. They have developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.”Wolfgang Daum, CEO of Knome
“NGS is rapidly being adopted by clinical and research laboratories worldwide. Easy-to-use analytical methods and software tools that aid the generation of accurate results are critical for the success of this groundbreaking new technology.”Dr. Lajos Pusztai, Professor at the University of Texas MD
Anderson Cancer Center
“Best of all, the HLA types reported were fully concordant with data obtained using SBT.”Mike Tayeb, DNA Genotek
"Omixon's Holotype HLA provided greater accuracy with fewer ambiguities, particularly for problematic specimens, than our Sanger SBT procedures."Dr. Pamela Kimball, VCU Health System Authority
"The NGS kit for HLA genotyping, unlike others available in the market, provides complete control of the reactions from the beginning to the end of the technical process, thus providing a higher cost-benefit ratio for the Laboratory. HLA TWIN is the best and most complete HLA genotyping program on the market and has helped us solve many problems in our laboratory routine."Dr. Rafael Cita, Fundação Pio XII Barretos
"Due to the higher throughput and resolution compared to Sanger sequencing, NGS technology improved significantly HLA typing. Omixon`s Holotype HLA workflow and HLA Twin software could be easily implemented in H&I laboratories. Generation of reliable data and ability to extend the typing to additional loci will allow providing better patient care not only in HSCT but also in organ transplantation."Dr. Milena Ivanova, Bulgarian Bone Marrow Registry